Self-perceived versus physician documented adverse events in patients with multiple sclerosis REGIMS-a pharmacovigilance registry for patients with multiple sclerosis in Germany.

Background: Post-marketing studies, including registries, mark an indispensable step in the establishment of drug side-effect profiles. In recent years, the inclusion of the patients' perspective has gained increasing relevance regarding pharmacovigilance.

Objective: Primary objective of this study was to analyse the concordance of subjectively experienced symptoms by multiple sclerosis (MS) patients treated with immunotherapy and the adverse events reported by their treating physicians.

Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.

Unlabelled: Fibrosis and steatosis are major histopathological alterations in chronic liver diseases. Despite various shortcomings, disease severity is generally determined by liver biopsy, emphasizing the need for simple noninvasive methods for assessing disease activity. Because hepatocyte cell death is considered a crucial pathogenic factor, we prospectively evaluated the utility of serum biomarkers of cell death to predict different stages of fibrosis and steatosis in 121 patients with chronic liver disease.